title: Oligofructose decreases serum lipopolysaccharide and plasminogen activator inhibitor-1 in adults with overweight/obesity.
abstract: To determine the effect of prebiotic supplementation on metabolic endotoxemia and systemic inflammation in adults with overweight and obesity.
  
  
  
  Samples from a previously conducted randomized, double-blind, placebo-controlled trial were used for analysis. Participants were randomized to 21 g of oligofructose (n = 20; BMI 30.4 kg/m2) or a maltodextrin placebo (n = 17; BMI 29.5 kg/m2) for 12 weeks. A total of 37 participants had samples available for the current analysis. Resistin, adiponectin, plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and macrophage chemoattractant protein-1 (MCP-1) were quantified using MILLIPLEX® assays. Lipopolysaccharide (LPS) was measured using PyroGene™ Recombinant Factor C Assay.
  
  
  
  Plasma LPS concentrations were reduced by 40% in the oligofructose group over 12 weeks compared to a 48% increase in the placebo group (P = 0.04). PAI-1, a risk factor for thrombosis, was reduced to a greater extent in the oligofructose group (-17.3 ± 2.6 ng/ml) compared to the placebo group (-9.7 ± 1.8 ng/ml; P = 0.03). Oligofructose did not affect IL-6, TNF-α, MCP-1, adiponectin, or resistin.
  
  
  
  Oligofructose reduces metabolic endotoxemia and PAI-1. Incorporating prebiotics into the diet through supplements or functional foods may help mitigate some markers of obesity-associated inflammation.
authors.affiliation: Department of Health and Physical Education, Mount Royal University, Calgary, Alberta, Canada.
authors.forename: Jill A
authors.initials: JA
authors.lastname: Parnell
authors.affiliation: Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.
authors.forename: Teja
authors.initials: T
authors.lastname: Klancic
authors.affiliation: Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.|Department of Biochemistry & Molecular Biology, Cumming School of Medicine, Calgary, Alberta, Canada.
authors.forename: Raylene A
authors.initials: RA
authors.lastname: Reimer
mesh_terms: D052242:Adiponectin / Q000097:blood; D000328:Adult; D015415:Biomarkers / Q000097:blood; D018932:Chemokine CCL2 / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D015850:Interleukin-6 / Q000097:blood; D008070:Lipopolysaccharides / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009844:Oligosaccharides / Q000494:pharmacology / Q000627:therapeutic use*; D050177:Overweight / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D056692:Prebiotics; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D015415:Biomarkers; D018932:Chemokine CCL2; C508600:IL6 protein, human; D015850:Interleukin-6; D008070:Lipopolysaccharides; D009844:Oligosaccharides; D017395:Plasminogen Activator Inhibitor 1; D056692:Prebiotics; C051321:SERPINE1 protein, human; D014409:Tumor Necrosis Factor-alpha; C120489:oligofructose